Business Context and Reporting Period
This Form 8-K Current Report was filed by Veracyte, Inc. on February 5, 2021, covering events occurring on February 4, 2021. The filing details a public equity offering and a strategic shift in the consideration method for the acquisition of Decipher Biosciences, Inc.
Key Financial Metrics and Transaction Details
- Equity Offering: 7,432,433 shares of common stock at a public offering price of $74.00 per share.
- Net Proceeds: Estimated at approximately $516.3 million after deducting underwriting discounts, commissions, and estimated expenses (excluding the underwriters' option).
- Over-Allotment Option: Underwriters granted an option to purchase up to 1,114,864 additional shares within 30 days.
- Acquisition Consideration: The company intends to convert the stock portion of the Decipher Biosciences merger consideration into cash, resulting in an all-cash transaction valued at $600 million (subject to purchase price adjustments).
Material Changes and Strategic Actions
The primary material change is the decision to substitute cash for the $350 million stock portion of the previously disclosed merger agreement with Decipher Biosciences. This election transforms the transaction into an all-cash deal, eliminating the need to file a Registration Statement on Form S-4. Consequently, the company now expects the transaction to close in March 2021, subject to regulatory approval and customary conditions.
Use of Proceeds and Outlook
Veracyte intends to use a portion of the net proceeds from the equity offering, combined with existing cash and cash equivalents, to finance the acquisition of Decipher Biosciences. Remaining proceeds will be allocated to working capital and general corporate purposes. The company reserves the right to use a portion of the proceeds for future acquisitions or investments in complementary businesses, though no specific commitments exist beyond the Decipher transaction.
Investor Verification Checklist
- Verify the final closing date of the equity offering (expected on or about February 9, 2021).
- Confirm whether the underwriters exercise the option to purchase the additional 1,114,864 shares.
- Monitor regulatory approval status for the all-cash acquisition of Decipher Biosciences.
- Review the final purchase price adjustments for the $600 million Decipher transaction.
- Check subsequent filings for the actual cash balance post-offering and post-acquisition.